Article Versions Notes

Snyder J, Atrash S, Paul B, Khan AM, Habib A, Shaikh H, Strouse C, Alkharabsheh O, Mazloom A, Ahmed N, et al. Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals. Cancers. 2025; 17(21):3569. https://doi.org/10.3390/cancers17213569

Snyder, Jordan, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Alma Habib, Hira Shaikh, Christopher Strouse, Omar Alkharabsheh, Anita Mazloom, Nausheen Ahmed, and et al. 2025. "Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals" Cancers 17, no. 21: 3569. https://doi.org/10.3390/cancers17213569

Snyder, J., Atrash, S., Paul, B., Khan, A. M., Habib, A., Shaikh, H., Strouse, C., Alkharabsheh, O., Mazloom, A., Ahmed, N., Mahmoudjafari, Z., Mushtaq, M. U., Zayad, A., McGuirk, J., Tiger, Y. K., Shah, M. R., & Abdallah, A.-O. (2025). Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals. Cancers, 17(21), 3569. https://doi.org/10.3390/cancers17213569